ALPHA TEKNOVA INC (TKNO)

US02080L1026 - Common Stock

8.71  +0.39 (+4.69%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TKNO. TKNO was compared to 56 industry peers in the Life Sciences Tools & Services industry. TKNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TKNO is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TKNO has reported negative net income.
TKNO had a negative operating cash flow in the past year.
TKNO had negative earnings in 4 of the past 5 years.
In multiple years TKNO reported negative operating cash flow during the last 5 years.

1.2 Ratios

TKNO's Return On Assets of -25.53% is on the low side compared to the rest of the industry. TKNO is outperformed by 67.86% of its industry peers.
TKNO has a Return On Equity of -36.30%. This is in the lower half of the industry: TKNO underperforms 60.71% of its industry peers.
Industry RankSector Rank
ROA -25.53%
ROE -36.3%
ROIC N/A
ROA(3y)-21.89%
ROA(5y)-13.43%
ROE(3y)-31.74%
ROE(5y)-19.4%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TKNO has a Gross Margin of 17.71%. This is amonst the worse of the industry: TKNO underperforms 82.14% of its industry peers.
TKNO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TKNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.91%
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

TKNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
TKNO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for TKNO has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 6.16 indicates that TKNO is not in any danger for bankruptcy at the moment.
TKNO has a Altman-Z score of 6.16. This is in the better half of the industry: TKNO outperforms 76.79% of its industry peers.
TKNO has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TKNO (0.12) is better than 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 6.16
ROIC/WACCN/A
WACC10.92%

2.3 Liquidity

TKNO has a Current Ratio of 4.73. This indicates that TKNO is financially healthy and has no problem in meeting its short term obligations.
TKNO's Current ratio of 4.73 is fine compared to the rest of the industry. TKNO outperforms 71.43% of its industry peers.
TKNO has a Quick Ratio of 3.94. This indicates that TKNO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.94, TKNO is in the better half of the industry, outperforming 67.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.73
Quick Ratio 3.94

More info and screens

4

3. Growth

3.1 Past

TKNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.92%, which is quite impressive.
TKNO shows a decrease in Revenue. In the last year, the revenue decreased by -0.99%.
The Revenue has been growing slightly by 5.43% on average over the past years.
EPS 1Y (TTM)46.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.88%
Revenue 1Y (TTM)-0.99%
Revenue growth 3Y5.43%
Revenue growth 5YN/A
Sales Q2Q%17.22%

3.2 Future

TKNO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.95% yearly.
The Revenue is expected to grow by 10.49% on average over the next years. This is quite good.
EPS Next Y42.87%
EPS Next 2Y27.28%
EPS Next 3Y18.95%
EPS Next 5YN/A
Revenue Next Year0.22%
Revenue Next 2Y5.98%
Revenue Next 3Y10.49%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TKNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TKNO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

TKNO's earnings are expected to grow with 18.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.28%
EPS Next 3Y18.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TKNO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA TEKNOVA INC

NASDAQ:TKNO (1/3/2025, 8:06:03 PM)

8.71

+0.39 (+4.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners11.05%
Inst Owner Change-12.64%
Ins Owners9.33%
Ins Owner Change0%
Market Cap464.33M
Analysts81.82
Price Target8.16 (-6.31%)
Short Float %2.79%
Short Ratio1.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.58%
Min EPS beat(2)-30.72%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)6.05%
Min EPS beat(4)-30.72%
Max EPS beat(4)21.57%
EPS beat(8)5
Avg EPS beat(8)1.56%
EPS beat(12)8
Avg EPS beat(12)-6.12%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)2.17%
Revenue beat(4)2
Avg Revenue beat(4)0.52%
Min Revenue beat(4)-7.36%
Max Revenue beat(4)7.66%
Revenue beat(8)5
Avg Revenue beat(8)3.49%
Revenue beat(12)9
Avg Revenue beat(12)6.48%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)45.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.77
P/FCF N/A
P/OCF N/A
P/B 5.32
P/tB 6.28
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.68
BVpS1.64
TBVpS1.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.53%
ROE -36.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.71%
FCFM N/A
ROA(3y)-21.89%
ROA(5y)-13.43%
ROE(3y)-31.74%
ROE(5y)-19.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.91%
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.33%
Cap/Sales 2.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.73
Quick Ratio 3.94
Altman-Z 6.16
F-Score4
WACC10.92%
ROIC/WACCN/A
Cap/Depr(3y)572.82%
Cap/Depr(5y)432.08%
Cap/Sales(3y)47.83%
Cap/Sales(5y)34.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.88%
EPS Next Y42.87%
EPS Next 2Y27.28%
EPS Next 3Y18.95%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.99%
Revenue growth 3Y5.43%
Revenue growth 5YN/A
Sales Q2Q%17.22%
Revenue Next Year0.22%
Revenue Next 2Y5.98%
Revenue Next 3Y10.49%
Revenue Next 5YN/A
EBIT growth 1Y10.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.48%
EBIT Next 3Y20.75%
EBIT Next 5YN/A
FCF growth 1Y71.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.08%
OCF growth 3YN/A
OCF growth 5YN/A